UCB's Global Corporate Website
Welcome to UCB in the United States

Mar

25

UCB at the 2022 AAD Annual Meeting: Our Commitment to Advancing Science in Dermatology

 

 

Mar

24

North Carolina Academic Engagement Night - Investing in our Future through STEM

At UCB, we are committed to accelerating scientific discoveries by supporting innovation ultimately leading to the discovery of new solutions to help people capture the moments that matter. Part of this commitment is a strong foundational support for STEM education in our communities to help inspire the next generation of scientists.

Mar

15

Voices on Value: Building a Sustainable Healthcare System Together – Our U.S. Sustainable Access and Pricing Transparency Report

Last year, UCB launched its Voices on Value blog series to foster a dialogue around how to make our health system better, stronger, and more accessible now and in the future. To advance this dialogue, UCB is releasing its first-ever U.S. Sustainable Access and Pricing Transparency Report, which underscores UCB’s commitment to an innovative, competitive, and value-based system. 

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Feb

25

Recognizing Rare Disease Day Every Day – The Importance of Addressing Unmet Patient Needs

At UCB, we work 365-days-a-year to find new ways to deliver solutions, peace of mind, and opportunities to people living with severe diseases because everyone deserves to live the best life they can.

Feb

22

Partnering for Greater Impact with Microsoft in R&D

At UCB, our aim is to amplify the power of scientific innovation through digital transformation, ensuring we deliver the best individual experience so patients can live their best lives. As part of that effort, we are integrating artificial intelligence (AI) across the research and development organization to bring accelerated solutions to patients with unmet needs. 

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Jan

19

UCB to acquire Zogenix

Jan

18

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study